SCHEMBL16154668

SCHEMBL16154668

CC(C)c1nc(-c2cc[nH]c(=O)c2)ccc1-c1ccc2c(c1)C(=O)NC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.43
MAPK1 P28482 3/20 0.43
DYRK1B Q9Y463 2/20 0.43
NTRK2 Q16620 2/20 0.43
TYRO3 Q06418 1/20 0.43
FYN P06241 1/20 0.43
MET P08581 2/20 0.42
NTRK1 P04629 2/20 0.42
FLT3 P36888 2/20 0.42
GSK3B P49841 2/20 0.42
JAK2 O60674 1/20 0.42
FGFR1 P11362 1/20 0.42
PRKACA P17612 1/20 0.42
KDR P35968 1/20 0.42
MAP2K2 P36507 1/20 0.42
MAP2K1 Q02750 1/20 0.42
MST1R Q04912 1/20 0.42
NTRK3 Q16288 1/20 0.42
CAMK1D Q8IU85 1/20 0.42
BRAF P15056 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16154661 0.93 CLK4 (0.49) CLK4MAPK1DYRK1BNTRK2TYRO3
SCHEMBL16133553 0.86 MAPK1 (0.42) CLK4MAPK1DYRK1BNTRK2TYRO3
SCHEMBL16135665 0.85 CLK4 (0.48) CLK4MAPK1DYRK1BNTRK2TYRO3
SCHEMBL16154657 0.84 MAP4K4 (0.45) MAPK1GSK3BBRAFMTORLRRK2
SCHEMBL16133537 0.83 BRD4 (0.39) MAPK1METBRAFMTORMAPT
SCHEMBL16154665 0.82 MAPK1 (0.44) CLK4MAPK1DYRK1BNTRK2TYRO3
SCHEMBL16135652 0.77 CLK4 (0.55) CLK4MAPK1DYRK1BNTRK2TYRO3
SCHEMBL16154663 0.72 CLK4 (0.54) CLK4MAPK1DYRK1BNTRK2TYRO3
SCHEMBL16154664 0.72 CLK4 (0.40) CLK4MAPK1DYRK1BNTRK2TYRO3
SCHEMBL15980672 0.72 CLK4 (0.51) CLK4MAPK1DYRK1BNTRK2TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210009555-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2021-01-14 US disclosed
US-9951043-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2018-04-24 US disclosed
US-20140303164-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2014-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210009555-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, RPL35 CLK4 4768/4885MAPK1 2037/4885DYRK1B 4883/4885
US-20140303164-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, G6PD CLK4 4766/4885MAPK1 2172/4885DYRK1B 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.